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Abstract
Background: Most people are initially infected with varicella zoster virus (VZV) at a young age and this infection
results in chickenpox. VZV then becomes latent and reactivates later in life resulting in herpes zoster (HZ) or “shingles”.
Often VZV infects neurons of the trigeminal ganglia to cause ocular problems, orofacial disease and occasionally a
chronic pain condition termed post-herpetic neuralgia (PHN). To date, no model has been developed to study orofacial
pain related to varicella zoster. Importantly, the incidence of zoster associated pain and PHN is known to be higher in
women, although reasons for this sex difference remain unclear. Prior to this work, no animal model was available to
study these sex-differences. Our goal was to develop an orofacial animal model for zoster associated pain which could
be utilized to study the mechanisms contributing to this sex difference.
Methods: To develop this model VZV was injected into the whisker pad of rats resulting in IE62 protein expression in
the trigeminal ganglia; IE62 is an immediate early gene in the VZV replication program.
Results: Similar to PHN patients, rats showed retraction of neurites after VZV infection. Treatment of rats with
gabapentin, an agent often used to combat PHN, ameliorated the pain response after whisker pad injection.
Aversive behavior was significantly greater for up to 7 weeks in VZV injected rats over control inoculated rats.
Sex differences were also seen such that ovariectomized and intact female rats given the lower dose of VZV
showed a longer affective response than male rats. The phase of the estrous cycle also affected the aversive
response suggesting a role for sex steroids in modulating VZV pain.
Conclusions: These results suggest that this rat model can be utilized to study the mechanisms of 1) orofacial zoster
associated pain and 2) the sex differences underlying zoster associated pain.
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Background
Varicella zoster virus (VZV) is a human herpesvirus that
infects a majority of the unvaccinated population world-
wide. While recovery from varicella “chickenpox” occurs
with lifelong immunity the virus persists in a latent state
in the nuclei of neurons within sensory and autonomic
ganglia across the entire neuro-axis. VZV chromatin re-
mains in the infected cells (extrachromosomal) but viral
protein expression and virus production remain re-
pressed [1–4]. However, reactivation from latency occurs
in about one third of VZV positive individuals to cause
herpes zoster (HZ), with the incidence of HZ increasing
with age and declining immune status. The skin rash of
HZ is often large but geographically restricted to a
dermatome infiltrated by one or two specific ganglia. Re-
activation is accompanied by extensive intra-ganglionic
spread, infection of multiple neurons and numerous in-
flammatory and physiological processes that contribute
to the development of pain. Almost all HZ is associated
with acute pain, with up to 90% of HZ patients seeking
prescription level pain relief [5]. However, some 30% of
HZ patients report a chronic pain state termed post her-
petic neuralgia (PHN), defined as pain lasting more than
3 months after the resolution of the skin lesions [6–8].
A fraction of PHN patients may suffer pain more than
one year after other disease symptoms dissipate [9].
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PHN is debilitating, difficult to treat, and can have sec-
ondary long term consequences that can greatly affect
quality of life. In the absence of the current HZ vaccine
approximately 1 million people annually in the US and
about 5% of the total population will suffer from PHN
[9–11]. The majority of HZ sufferers are age 60 years or
older [12, 13]. Given that the number of people 60 years
of age or older is one of the fastest growing and is
expected to double in the next 50 years [9], HZ and the
associated pain will be an ever increasing problem in the
future. While the HZ vaccine reduces the incidence of
HZ by 51% and PHN by 68%, the vaccine remains to be
widely used largely due to cost/reimbursement issues,
reluctance to vaccination, and ignorance of both the tar-
get population and their physicians. [11]. Even if every
candidate receives the vaccine (which is far from being
achieved) the US would still have some half million HZ
cases each year with many suffering from PHN. As such,
better prevention and therapy for both zoster and PHN
are an unmet need.
It has been difficult to model HZ and PHN because
no animal model shows reactivation of latent VZV. In
general, VZV is considered human specific, for reasons
not yet clear. However it has been shown that VZV
injected into the footpad of either Wistar or Sprague
Dawley rats results in measurable hypersensitivity that is
similar to that in humans with PHN [14–20]. The foot-
pad animal model has been developed as a platform for
one, mechanistic studies of chronic pain after VZV in-
fection of dorsal root ganglia and two, for drug evalu-
ation focused on HZ associated pain relief [20, 21].
Treatment of these animals with antivirals, opioids or
NSAIDS mirrors HZ patients treated with these same
drugs, in that, zoster associated pain does not respond
to antivirals, but does respond to treatment with gaba-
pentin or sodium channel blockers [16, 17, 20, 21].
Given that the rat footpad model has been used to study
the mechanism by which VZV associated pain develops and
can be used for pre-clinical screening of analgesic drugs
[17, 21] we considered whether the model can be extended
to orofacial pain that follows VZV reactivation in the tri-
geminal ganglia. Extension of the model to the orofacial re-
gion would be significant because the trigeminal ganglia of
human cadavers have the highest latent VZV load, and up
to 1 in 5 HZ cases occurs in the orofacial or naso-ocular re-
gion [22, 23]. Importantly, females report HZ associated
pain 3.75 times more often than men, and HZ associated
pain has been reported to be 36% higher in females
[24, 25]. The basis for this disparity is not understood.
Currently, neither the orofacial effects nor the sex differ-
ences have been determined in any zoster associated pain
model. In this report, an animal model for zoster associated
orofacial pain was characterized that could be utilized first,
to study the mechanisms of HZ associated pain in the
orofacial region and second, to study the mechanisms
resulting in women reporting HZ pain more often than
men.
Methods
Cells and viruses
VZV Parent of Oka (pOka), a varicella isolate that was
the parent strain used to derive the current VZV vaccine
strain, was used in all this work. pOka VZV was previ-
ously shown to induce chronic pain indices in the rat
model [15]. Virus was used at less than 12 passes beyond
receipt from M. Takahashi (Osaka University, Japan) and
propagated as detailed previously [26, 27] on the VZV per-
missive MeWo human cell line (ATCC, Manassas, VA).
Cells and virus were grown in Minimal Essential Media
(MEM) supplemented with 10% fetal bovine serum (FBS)
and antibiotic and antimycotic mixture (Sigma, St. Louis,
MO). VZV was prepared to high titer as previously de-
tailed [15] on confluent monolayers of MeWo cells in-
fected at ~0.1 plaque forming units (pfu)/cell. Virus
infected cells incubated at 35 °C for 48–72 h post infection
were harvested by trypsin digestion, and optimal VZV cell
viability was maintained by slow freezing aliquots in MEM
containing 20% FBS and 10% dimethyl sulfoxide (Sigma,
St. Louis, MO), followed by storage under liquid nitrogen.
Virus titers of frozen stocks were assessed by an infectious
center assay. Uninfected cell equivalents were prepared
using similar treatments. All virus and cellular stocks were
provided by Dr. Kinchington’s laboratory.
Animal studies
All work with animals was approved by the Texas A&M
University College of Dentistry Institutional Animal Care
and Use Committee. Male and female Sprague-Dawley
or Long Evans rats (280–300 g) were purchased from
Envigo (Indianapolis, IN) and kept on a 14:10 light/dark
cycle. The rats were given food and water ad libitum.
After a 4 day acclimation period, experiments were car-
ried out in accordance with NIH regulations on animal
use. Vaginal smears were performed daily on female rats
to determine the stage of the estrous cycle. The body
weights were recorded weekly. Six experiments using
different batches of rats (see Table 1) were completed to
measure behavior after injection of a high (1900 pfu/μl)
or low (650 or 360 pfu/μl) dose of VZV (pOka strain).
Male Sprague-Dawley rats were used in the experiments
unless otherwise indicated.
Training for thermal and mechanical hypersensitivity assay
In the first experiment the animals were trained to ob-
tain reward using the orofacial test chamber from Ugo
Basile (Italy) [28–30]. The reward was a sweetened con-
densed milk mixture, 100 ml milk and 200 ml water.
Drinking time was measured by using an infrared beam
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that detects when the animal has placed their nose into
the spigot area to access the drinking supply. No thermal
testing or filament testing was performed during the ini-
tial one week training period where the animals were
placed in the chambers daily for 10 min to obtain a re-
ward. No filaments or thermal coils were present in the
training period. Next, the pre-testing training period
continued another two weeks and included a daily 12 h
fast followed by 10 min of familiarization with the cham-
ber environment with the reward inaccessible and
10 min of active testing with the reward accessible.
Training was successful when animals consistently drank
milk for 300 ± 50 s out of a 600 s testing period with
thermal coils or filaments in place at the spigot opening.
All testing was done in the beginning of the dark phase
with red lights.
To measure thermal and mechanical hypersensitivity
induced by VZV the animals were anesthetized briefly
with 2% isoflurane using a 2 l per minute flow of air, the
whisker pad of Sprague Dawley rats were then inocu-
lated with uninfected MeWo cells, or the same number
of MeWo cells infected with (1900 pfu/μl) VZV by
injecting a 100 μl volume subcutaneously. The animals
were mobile within 5 min of the injection. The whisker
pad was chosen as the injection site because it has a
large number of sensory terminals that would allow for
infection of VZV. Testing was completed either before
the injection (pre-injection) or one week after injection.
Testing continued once every seven days thereafter. For
the thermal test the coils of the test chamber were set to
45 degrees Celsius. For the filament test, twelve nickel/
titanium/chromium wires 0.16 mm (0.006″) in diameter
were placed evenly around a circular opening 3.5 cm in
diameter. Each wire projected 1.5 cm into the center of
the opening. The weekly test schedule assessed baseline
responses without either a thermal coil or a filament on
the first day of each week, followed by thermal testing
the following day and filament testing on the next day.
Testing was done for a 6 week period.
Place escape/avoidance paradigm (PEAP) testing in
male rats
In a second experiment behavioral responses were mea-
sured using the PEAP test. Testing was completed by a
tester blinded to the treatment. For this experiment the
whisker pad of a second group of male rats was injected
with a high dose of VZV (1900 pfu/μl), or equivalent
control MeWo cells or PBS (100 μl volume). Rats were
anesthetized as described previously for the injection. At
7 days post inoculation the animals were placed in a
30 cm X 30 cm X 30 cm acrylic box in which half the
box was covered in black cloth. This test chamber was
Table 1 Experiments completed for each study (i.e. set of animals)
Study Experiment Groups Number of animals
(male Sprague Dawley
rats unless otherwise indicated)
Study #1 Thermal and mechanical hypersensitivity
assay (Figure 3).
Neurite retraction study using PGP 9.5
(n = 3/group randomly selected, Figure 2).
Mewo (control)
Poka (VZV)
n = 10
n = 10
Study #2 Place escape/avoidance paradigm (Figure 4).
VZV infection detected with IE62 marker (Figure 1).
PBS (vehicle)
Mewo (control)
Poka (VZV virus)
n = 6
n = 6
n = 6
Study #3 Gabapentin assay (Figure 5). Mewo/vehicle
Mewo/gabapentin
Poka/vehicle
Poka/gabapentin
n = 5
n = 5
n = 5
n = 5
Study #4 Sex differences study comparing males and
females (Figure 6).
Mewo/female
Mewo/male
Poka/female
Poka/male
n = 24
n = 7–15
n = 25
n = 7–15
Study #5 OVX females as compared to males (Sprague
Dawley and Long Evans, Figure 7).
VZV infection detected with IE62 marker
(Sprague-Dawley rats, no figure).
Mewo/male
Mewo/female
Mewo/OVX female
Poka/male
Poka/female
Poka/OVX female
n = 5
n = 4
n = 4
n = 7
n = 6
n = 6
n = 5 (Long Evans) for all
treatment groups
Study #6 Female estrous cycle study (Figure 8). Mewo diestrus
Mewo proestrus/estrus
Poka diestrus
Poka proestrus/estrus
n ≥ 8
n ≥ 8
n ≥ 8
n ≥ 8
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modeled from the PEAP test performed and detailed by
the Fuchs lab [31]. PEAP testing has been used in in-
flammatory and neuropathic pain models, used in both
sexes and various strains and ages of rats as a means of
measuring affective aspects of pain [31–37]. Each indi-
vidual rat was placed into the chamber; rodents being
nocturnal prefer the dark side of the chamber. The study
was then initiated by stimulating the face with a 60 g
filament every 15 s; rats on the dark side of the chamber
receive a stimulus at the injected side, whereas rats with
their head on the clear side of the chamber were stimu-
lated on the contralateral non-injected side. The region
receiving the stimulus was in the region below the eye
and caudal to the whisker pad, which is innervated by
the second branch of the trigeminal ganglia. Because
sensory neurons of the second branch also innervate the
whisker pad, we expected sensitivity of the face around
the eye [38]. The time spent on the dark side of the box
was recorded in 5 min bins and testing was performed
for a total of 30 min on the test day. Testing was per-
formed one day a week and continued for 8 weeks.
VZV injection in male rats to investigate analgesia
efficacy
A third group of male rats were injected at the whisker
pad with either a low dose of VZV (360 pfu/μl) or control
MeWo cells. One week after VZV injection the rats were
given a 3.5 ml gavage of either 0.9% saline, or 50 mg/ml
gabapentin (Amneal Pharmaceuticals, Branchburg, NJ).
PEAP testing was performed 30 min after gavage. The ef-
fect of analgesics can be undetectable “swamped out” if
the nociceptive response is too great thus, the lowest dose
of VZV known to elicit a behavioral response was imple-
mented before administration of gabapentin.
Sex differences in VZV induced aversive behavior
In a fourth set of studies intact male and intact female
rats were injected with 650 pfu/μl of VZV or equivalent
control MeWo cells. PEAP testing was performed once
a week over a six week period.
Compare VZV induced aversive behavior of
ovariectomized females to intact males
Female rats were ovariectomized to simulate menopause
because a majority of women with HZ pain will be in a
post-menopausal state and post-menopausal women re-
port HZ associated pain more than older men. In this
fifth study intact male, intact female and OVX females
from two strains of rat were utilized (Sprague Dawley
and Long Evans rats). Sprague Dawley rats were inocu-
lated with 650 pfu/μl of VZV and Long Evans rats were
inoculated with 360 pfu/μl of VZV. PEAP testing was
performed 7 days after injection and continued once a
week for 2 weeks. Long Evans rats were reported by
Envigo to be less docile than Sprague Dawley rats and
thus, the Long Evans rats were injected with a lower
dose of VZV as compared to the Sprague Dawley rats in
Study #5. This lower dose was expected to compensate
for the greater inherent activity of Long Evans rats dur-
ing the behavioral testing.
Ovariectomy surgery
Animals were anesthetized with 2% isoflurane using a 2 l
per minute flow of air. The anesthetized female was placed
in ventral recumbency with their tail toward the surgeon.
The dorsal surgical area was shaved and swabbed with sur-
gical scrub. A short dorsal midline skin incision was made
halfway between the caudal edge of the ribcage and the
base of the tail. An abdominal muscle wall incision was
made lateral to the spine to provide access to the periton-
eal cavity. The ovary and the oviduct were exteriorized
through the muscle wall incision. A sterile silk ligature was
placed around the oviduct. Each ovary and part of the ovi-
duct was removed with a single cut through the oviduct
near the ovary. The remaining tissue was replaced into the
peritoneal cavity and the opening sutured. The ovary on
the contralateral side was removed in a similar manner
and the animal was given a 2 mg/kg dose of nalbuphine.
Compare VZV induced aversive behavioral response over
estrous cycle
In a sixth set of studies vaginal smears were taken im-
mediately after PEAP testing each week using the intact
females from the fourth study. The groups were then di-
vided based on the phase of the estrous cycle.
Immuno-fluorescent staining
After testing for hypersensitivity or aversive behavior the
rats were sacrificed and perfused for immunohistochem-
istry. Whisker pad tissue was collected from the first
study and trigeminal ganglia were collected from the
second study and fifth study (see Table 1). Because VZV
infection, as determined by the presence of IE62, showed
greater levels of IE62 at 1 month and 18 months post in-
fection versus one week post infection [39]. Thus, we ex-
pected greater VZV infection and neurite retraction in
the first and second studies that were of longer duration.
Tissue in study five was analyzed to determine if the sex
differences were due to differences in VZV infection.
After administering 100 mg/kg ketamine/10 mg/kg xyla-
zine the rats were perfused with 9% sucrose followed by
4% paraformaldehyde. Fixed tissues were stored in 25%
sucrose, frozen, cryo-sectioned and the 20 μm sections
placed on Histobond slides (VWR international, Radnor,
PA). The tissue was then blocked with a PBS solution con-
taining 5% normal goat serum and 0.3% Triton-X 100 for
2 h at room temperature. The slides were incubated in a
primary antibody solution overnight at 4 °C. Primary
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antibodies consisted of a 1:200 dilution of the mouse
monoclonal IE62 antibody (Acris Antibodies Inc., San
Diego, CA) and a 1:250 dilution of the rabbit monoclonal
NeuN antibody (Abcam, San Francisco, CA); or a 1:500
dilution of the rabbit polyclonal PGP9.5 antibody (BioRad,
Raleigh, NC). Primary antibodies were diluted with PBS,
5% BSA and 0.3% Triton X-100. After incubation in pri-
mary antibody the slides were rinsed three times in PBS
and Triton-X 100 for a total of 45 min and placed for 2 h
in a 1:500 dilution of secondary antibody in PBS and 0.3%
Triton X-100. Secondary antibodies included a mixture of
goat anti-mouse 568 and goat anti-rabbit 488 1:500 dilu-
tion (Invitrogen, Carlsbad, CA). For the PGP9.5 antibody
staining a 1:500 dilution of a goat anti-rabbit 568 second-
ary was used. After rinsing the slides three times in PBS for
a total of 45 min, the slides were then mounted with
Fluoromount-G mounting medium containing Hoechst
33,342 stain (Electron Microscopy Sciences, Hatfield, PA).
The fluorescent signal was imaged using a Nikon fluores-
cent microscope and NIS-Elements imaging software
and a Photometrics CoolSnap K4 CCD camera (Roper
Scientific, Inc., Duluth, GA).
Cell counting
Quantitation of IE62 staining was completed by a blinded
reviewer counting the number of IE62 and NeuN positive
cells within a randomly chosen 0.5 mm circular field near
either the V3 branch or the V1/V2 branches. The neurons
were primarily circular in shape and were divided into
small C-fibers (<23 μm diameter), A-δ medium-sized (23–
32 μm diameter) and A-α/β large neurons (32 > μm diam-
eter) based on findings from the dorsal root ganglia [40].
Or the counts for all NeuN positive cells were combined.
Three randomly chosen trigeminal ganglia sections were
analyzed for each animal. Three animals were randomly
chosen from each treatment group.
Measurement of neurite infiltration was performed as
recently detailed [15]. Sections were counted for PGP9.5
positive neurites in coronal whisker pad sections, and
were determined by a reviewer blinded to the treatment
group. All PGP9.5 positive filaments that crossed the
stratum basale/dermis border terminating between the
surface of the skin and this border were counted; counts
were determined along each mm of skin in the section.
Neurite counts were completed by choosing a single
random field ~5 mm in length along the stratum basale/
dermis border on 10 randomly chosen sections taken
from three randomly chosen animals from each treat-
ment group. The number of filaments counted per mm
of skin for each section was reported.
Statistical analysis
Data was analyzed with ANOVA and each time point
was considered a replication. Dependent variables
included the hypersensitivity measurements, PEAP data
or cell counts and the independent variables were treat-
ment, sex, cell size and trigeminal ganglia branch. When
a significant effect was observed Bonferroni post-hoc
tests were completed (Prism 5.04, GraphPad Software,
La Jolla, CA, or Abstat, Anderson Bell Corp, Arvada
CO). When two groups were being compared a two-
tailed Mann-Whitney t-test was performed. The number
of animals per group is outlined in Table 1.
Results
VZV accesses the trigeminal ganglia after whisker pad
inoculation
In the virus injected group NeuN positive cells co-localize
with IE62 within the trigeminal ganglia (Fig. 1a and b).
IE62 is one of the first proteins translated from the VZV
genome after infection. IE62 is an essential intermediate
early gene that regulates expression of most VZV genes
and the production of VZV localizes to both the nucleus
and cytoplasm [41]. From the image the majority of IE62
was in the neuronal cell population but an analysis of
other cell types was not completed. In these male rats
IE62 staining was in neurons of all sizes (Fig. 1c) but there
was a significantly greater percent of IE62 in the smaller
neurons, F(2, 68) = 8.02, p < 0.001 and this staining was
significantly greater in the region innervated by the V1/V2
branch, F(1, 68) = 17.09, p < 0.001 (Fig. 1d). Note that the
whisker pad injection site is innervated by the V2 branch
of the trigeminal ganglia. No IE62 stain was observed in
the MeWo or PBS groups (data not shown).
As in humans virus infection induces neurite retraction
Skin biopsies of zoster patients suffering PHN have re-
duced peripheral innervation of the skin in comparison
to zoster patients not suffering from PHN [42, 43]. This
was also recently found in the rat footpad PHN model
[44]. We therefore examined peripheral innervation of
neurites at the whisker pad, using PGP9.5 staining to
identify and visualize neurites (Fig. 2a, b). Rats showing
hypersensitivity due to VZV injection (pOka strain) had
a significantly reduced peripheral innervation of the
whisker pad skin (Fig. 2c).
Development of pain behaviors after VZV inoculation of
the whisker pad
Whisker pad injection of MeWo cells infected with VZV
(pOka strain) revealed the development of some facial ther-
mal hypersensitivity F(1170) = 7.1, p < 0.01 as compared to
control uninfected cells (Fig. 3a). There was no significant
interaction of treatment and time F(1170) = 0.63, p = 7.2.
Testing for mechanical hypersensitivity showed a significant
response over the 51 day testing period F(1170) = 16.3,
p < 0.0001 with no significant interaction between treat-
ment and time F(1170) = 1.7, p = 0.1 (Fig. 3b). Post-hoc
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testing revealed a significant difference between the pOka
and MeWo treatment groups at days 15 and 23 (Fig. 3b).
In addition to measuring thermal and mechanical
hypersensitivity a PEAP test was completed after whisker
pad injection. In this assay, reduced time on the dark
side during the stimulation phase indicates a greater
affective pain response [31]. The response to VZV
injection showed a remarkable difference that was signifi-
cant for 7 weeks in comparison to control (Fig. 4). Signifi-
cance was observed in week one, F(2,75) = 19.9,
p < 0.001 (Fig. 4a); week two F(2,75) = 196.1, p < 0.001
(Fig. 4b); week three F(2,75) = 31.3, p < 0.001 (Fig 4c);
week four F(2,75) = 14.7, p < 0.001 (Fig. 4d); week five
F(2,75) = 20.1, p < 0.001 (Fig. 4e); week six F(2,75) = 5.2,
p < 0.05 (Fig. 4f ); and week seven F(2,75) = 6.4, p < 0.01
(Fig. 4g). The effect of virus in week eight was no longer
significant, F(2,75) = 2.4, p = 0.12 (Fig, 4h). A significant
interaction between the PBS, MeWo and virus pOka
groups was observed in weeks two F(10,75) = 5.8,
p < 0.001 (Fig. 4b) and three F(10,75) = 2.5, p < 0.05 (Fig.
4b). No significant interaction was observed in the other
weeks (data not shown). Post hoc testing demonstrated a
difference between the VZV and control groups for 7 out
of the 8 weeks (Fig. 4a-g) but after eight weeks, there was
no significant difference (Fig. 4h). These results strongly
suggest the development of a virus specific pain response
that did not develop after injecting uninfected cells or
PBS. The PEAP assay was found to be more indicative
and sensitive to changes resulting from virus injection and
thus, the PEAP assay was continued throughout the rest
of the following studies. During the first 5 min there was
no significant difference in the time spent on the light side
of the box when comparing groups in the first week to fol-
lowing weeks. This data suggests the animals do not recall
the events of previous week when the 30 min testing pe-
riods are separated by a 7 day period of no testing.
VZV induced orofacial pain responds to gabapentin.
Seven days after injecting the whisker pad (360 pfu/μl
VZV), gabapentin was administered by oral gavage. In-
jection of virus induced a pain response F(2, 171), 13.41,
p < 0.01 (Fig. 5), however gabapentin significantly F(2,
171) = 6.75, p < 0.01 reduced this response 30 min after
administrating gabapentin. Post-hoc testing demon-
strated that gabapentin significantly reduced the re-
sponse at the 15, 20, 25 and 30 min testing periods
(Fig. 5). A significant virus/drug interaction was observed
F(2, 171) = 7.77, p < 0.01. No significant differences were
observed between the MeWo/vehicle and MeWo/gaba-
pentin treatment groups.
Sex based differences in the development of VZV induced
pain at the whisker pad.
We carried out a comparison of the pain response in male
and female rats to determine if sex differences exist in this
virus model. One week after VZV injection, the PEAP re-
sponse significantly increased in the virus versus MeWo
control group F(1, 395) = 19.1, p < 0.001 (Fig. 6a) in both
sexes of rats, and there was no significant difference be-
tween the sexes F(1, 395) = 0.03, p = 0.85. In contrast, two
weeks F(1, 443) = 12.1, p < 0.001 and three weeks after
Fig. 1 The VZV marker IE62 was expressed in neurons of the
trigeminal ganglia after injecting the whisker pad with virus. Sprague
Dawley rats from the second study were injected with 100 μl of 1900
pfu/ μl VZV and tissues were collected 8 weeks following injection.
Immunofluorescent detection of IE62 (red) and the neuronal marker
NeuN (green) was completed on fixed frozen sections. Blue was nuclear
Hoeschst stain. A sagittal section of the trigeminal ganglia is shown in
panel a (low magnification) and in b (high magnification). In panel a
the boxed area within the cartoon shows the stained region of the
trigeminal ganglia. Yellow cells co-labeled with IE62 and NeuN in panel
a are indicated by arrowheads. The branches of the trigeminal ganglia
are labeled V1, V2 and V3. The V3 border is represented by a dotted line.
In panel b, co-localization of NeuN and IE62 was shown in yellow and
cells were indicated by arrows. Bar equals 50 μm. Panel c shows the
total number of NeuN and double stained NeuN and IE62 positive cells
in the trigeminal ganglia. Panel d, the percent of NeuN/IE62 double
labeled cells in the total NeuN positive population was calculated for
the neurons in different regions of the trigeminal ganglia. Small
neurons were <23 μm in diameter, medium-sized neurons were
23–32 μm in diameter and large neurons were >32 μm in diameter. An
asterisk indicates p < 0.05, n = 6. Values shown are the mean and SEM
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injection F(1, 473) = 11.0, p < 0.01 there was a significantly
greater pain response in the virus versus control group for
the females but not the males (Fig. 6b and c). Moreover,
the difference between male and female virus groups was
significant in week two F(1443) = 16.6, p < 0.001 (Fig. 6b),
three F(1, 473) = 15.4, p < 0.001 (Fig. 6c), four F(1,
473) = 10.6, p < 0.01 (Fig. 6d) and five F(1, 473) = 8.4,
p < 0.01 (Fig. 6e). This sex difference was no longer sig-
nificant in week 6 (Fig. 6f). No significant interaction be-
tween sex and virus was observed in week one and five
but in week two, three and four a significant interaction
was observed F(1443) = 4.9, p < 0.05, F(1, 473) = 16.8,
p < 0.001, F(1, 473) = 11.0, p < 0.01, respectively.
Our data also show that a dose response to VZV oc-
curred, in that a lower responses was detected after
injecting a lower VZV dose of 650 pfu/ml (Fig 6) con-
trasted to the more significance responses seen with the
higher VZV dose in Fig. 4 (1900 pfu/ μl). With the lower
VZV dose, significant behavioral responses were much
shorter in male rats, lasting for only one week (Fig. 6),
while the pain response to a higher dose lasted for seven
weeks (Fig. 4).
Pain was reduced in male rats versus female rats in a
post-menopausal state
Because a majority of females suffering from PHN are post-
menopausal and have low levels of plasma estradiol the
pain response of ovariectomized females was compared to
males. Sprague Dawley rats injected with virus (650 pfu/μl)
showed a significant response F(1, 144) = 117.0, p < 0.001
in the first week but there was no significant sex difference
(Fig. 7a). Two weeks after VZV infection the intact and
OVX females showed significantly greater behavioral re-
sponse than males (Fig. 7b). Long Evans rats also had a sig-
nificant response to VZV infection (360 pfu/μl) in the first
week F(1, 144) = 74.5.0, p < 0.001 and two weeks after
VZV inoculation the intact female and OVX female rats
had a significantly greater response than males (Fig. 7d).
Fig. 2 VZV induced peripheral retraction of PGP9.5 positive neurites
in the skin of the whisker pad. At six weeks after whisker pad
injection with either MeWo cells (a) or MeWo cells containing VZV
(b) male Sprague Dawley rats from the first study were sacrificed
and the whisker pad skin processed for analyses. Ten 20 μm coronal
sections were cut from each injected whisker pad. Representative
images for MeWo injected (a) and pOka injected (b) rats are shown
after staining with the PGP9.5 antibody (red), cell nuclei are stained
blue. The border between the stratum basale and dermis is shown
as a white dotted line. Arrows point to PGP9.5 positive filaments.
Asterisk above the arrow indicates enlarged region within box.
Bar = 50 μm. In panel c, each data point on the histogram shows
the average number of PGP9.5 positive neurites per mm that
terminate above or cross the basale/dermis border for each section.
There were ten sections per rat and three rats per treatment group.
An asterisk indicates p < 0.05. Mean and SEM are shown
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The increased pain response observed in female rats was
not the result of greater viral infection
Two weeks of PEAP testing the animals were sacri-
ficed and the ganglia isolated for immunostaining
with the VZV marker IE62. The percentage of tri-
geminal ganglia neurons (NeuN positive) staining for
the VZV marker IE62 was 16% ± 1.5 for the intact
Sprague Dawley females, 10% ± 1.3 for the OVX
females and 28% ± 3.7 for the males. The males had
a significantly greater percentage of neurons staining
for IE62 (p > 0.05) as compared to the females and
there was no significant difference between the intact
and OVX female groups.
Aversive behavioral response in cycling females after VZV
injection
The behavioral response after VZV injection of the whis-
ker pad was determined during the estrous cycle. In
Fig. 8 the estrus and proestrus data were combined
and the diestrus I and diestrus II (i.e., metestrus) data were
combined because of their similar estradiol levels (data
not shown). A significantly greater response was observed
in rats with low estradiol (Diestrus pOka) versus the rats
with higher plasma estradiol (Proestrus/estrus pOka) in
week one F(1, 281) = 5.8, p < 0.05 (Fig. 8a, n≥8), two F(1,
281)= 4.4, p<0.05 (Fig. 8b), three F(1, 281)= 61.6, p<0.001
(Fig. 8c) and four (1, 281)= 12.4, p<0.01 (Fig. 8d). No sig-
nificant cycle response was observed in weeks five and six
(data not shown). During the first F(1, 281)= 19.2,
p<0.001, second F(1, 281)= 11.2, p<0.01, third F(1, 281)=
21.2, p<0.001, fourth F(1, 281)= 4.3, p<0.05 week there
was a significant virus effect. A significant interaction be-
tween cycle and virus treatment was observed in week
two F(1, 281)= 9.4, p<0.01, three F(1, 281)= 21.3, p<0.001
and four (1, 281)= 14.6, p<0.001. Post-hoc testing indi-
cated a significant decrease in the Diestrus pOka group
versus the Diestrus MeWo group at the 15, 20, 25 and
30 min time points in weeks one, two, three, and four. No
significant difference was observed in week five and six.
These results indicate that the development of pain re-
sponses to VZV is influenced by the stage of the es-
trous cycle.
Fig. 3 Thermal and mechanical hypersensitivity increased after
inoculating the whisker pad with VZV. Male Sprague Dawley rats were
injected with either MeWo cells or MeWo cells infected with 1900 pfu/
μl VZV. Testing was performed for 50–51 days post injection. Testing
was completed using the orofacial test module from Ugo Basile.
Thermal testing (panel a) was completed at 45 °C and filament testing
(panel b) was performed with a custom circular opening containing 12
filaments. Fewer seconds drinking is an indicator of greater hyperalgesia
or allodynia. Asterisk indicates a significant difference (p < 0.05) between
the MeWo and VZV (pOka) treatment groups. There were 10 animals
per treatment group and values are the mean and SEM
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Fig. 4 VZV increased aversive behavior as measured by the Place Escape/Avoidance Paradigm (PEAP) test. PEAP was completed on males whose
whisker pad was injected with either PBS (vehicle), MeWo cells or MeWo cells infected with VZV (1900 pfu/ μl). The PEAP test was performed for
eight weeks and each panel shows the data for a different week; panel a shows week 1, panel b week 2, panel c week 3, panel d week 4, panel
e week 5 and panel f week 6, panel g week 7 and panel h week 8. The upper row of asterisks indicate a significant difference (p < 0.05) between
the PBS and pOka treatment groups. Asterisks on the lower row indicate a significant difference (p < 0.05) between MeWo and pOka treatment
groups. There were 6 animals per treatment group
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Discussion
Mechanical allodynia is the most common, most debili-
tating and the most difficult to treat component seen in
PHN patents. Persistent mechanical allodynia and ther-
mal hyperalgesia are present after VZV inoculation of
the footpad [14–20]. The study here expands the footpad
model to the orofacial region by demonstrating that
VZV induces a significant behavioral response after
stimulating the facial region [20, 21, 44]. These re-
sponses included thermal and mechanical hypersensitiv-
ity, as well as, an aversive response. Interestingly the
aversive response, as measured by the PEAP assay [31],
lasted several weeks longer than the hypersensitivity
measured by Ugo Basile chambers. The longer PEAP re-
sponse suggests that either the PEAP assay was more
sensitive than the Ugo Basile chambers in measuring re-
sponses or that the affective component is present lon-
ger than the sensory component. In contrast to our
results, previous studies injecting compete Freund’s adju-
vant into the paw showed that sensory responses (von
Frey) and affective responses (PEAP test) lasted for similar
times [31]. One explanation for this inconsistency would
be that adjuvant induces pain through a different mechan-
ism than VZV. Behavioral tests, such as the PEAP test, re-
quire supraspinal pain processing and would be useful in
the drug development for patients [36, 37]. In one ex-
ample of preclinical drug testing, gabapentin reduced the
affective PEAP response in this rat model consistent with
gabapentin being efficacious in treating patients with HZ
associated pain [45]. It is interesting to note that anxiety-
like behaviors were not reversed by gabapentin treatment
in previous studies [20], but gabapentin does effect the
PEAP measurement (reverse the aversive behavior), con-
sistent with the idea that anxiety does not bias the PEAP
measurement [36, 46].
Pain is reported 3.75 times more often in women than
in men after HZ infection [25] but no model currently
exists to study this sex difference. We show here that
VZV induced pain was influenced by sex. VZV inocu-
lated female rats experienced the same level of aversive
behavior as the VZV injected males post-injection week
1, but by week 2 females clearly experienced a higher
level of pain behavior, consistent with females experien-
cing more orofacial pain-related sensations [47–49]. One
reason for the sex difference could be related to sex ste-
roids. Of note is the fact that the males had a greater
percentage of IE62 positive neurons but showed less
aversive behavior suggesting that viral infection rates do
not explain the sex difference. Moreover, our data sup-
port a role for sex steroids because during the estrous
cycle there was a significantly greater PEAP response in
diestrus rats (when estradiol is low) in comparison to
proestrus/estrus rats (when estradiol is higher). This data
is consistent with the nociceptive response in an inflam-
matory TMJ model where rats given a diestrus level of
estradiol (low) had a greater nociceptive response in
comparison to rats given a proestrus dose of estradiol
(high) [50]. Mechanistically estradiol has been shown to
alter the pain response through G-protein signaling [51].
Moreover, estradiol utilizes G-protein signaling to alter
the nociceptive response by changing the responsiveness
of N-methyl-D-aspartic acid (NMDA) receptors and by
enhancing dendritic spine growth [52]. Although the
mechanism is unclear as to why the nociceptive re-
sponse was higher in females this animal model can be
used to explore the mechanisms contributing to the ob-
served sex difference.
Humans with HZ associated pain do not require con-
tinued replication of VZV because administration of the
antiviral acyclovir (blocks viral replication) does not re-
duce the pain response [53]. Similarly, VZV induced
pain was not ameliorated by antiviral agents in the rat
footpad model [54]. As in humans, VZV induced hyper-
sensitivity in rodents can be present without detectable
Fig. 5 Gabapentin relieves the VZV induced aversive response. The
PEAP test was assessed at 7 days post infection in rats whose
whisker pad was injected with either MeWo cells or MeWo cells
infected with a low dose of VZV (360 pfu/ μl). An asterisk indicates a
significant difference between the VZV pOka/vehicle group and the
VZV pOka/gabapentin group, as well as, a significant difference
between the Mewo/vehicle group and the pOka/vehicle group.
There were 5 animals per treatment group
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viral replication [44, 55, 56]. Recent work has indicated
that VZV goes through a partial replication cycle in ani-
mals resulting in translation of viral proteins that can in-
duce pain [53]. Together the data suggests continued
production of lytic virus and necrosis of neurons is not a
mechanism for induction or maintenance of the pain re-
sponse [57]. To date, no animal has supported VZV gan-
glionic reactivation [58], so PHN after reactivation cannot
be studied. Interestingly, Dr. Kinchington’s group has
recently reported the first reliable experimental VZV re-
activation in vitro using human neuron cultures [59] and
proposed that both human PHN and pain in rats are the
result of VZV gene expression without viral replication.
Our studies add to this previous work by extending the
pain response to the orofacial region which contributes to
pain in up to 28% of herpes zoster patients [22, 23]. Using
this novel model of VZV these pain mechanisms can be
determined in the orofacial region.
Fig. 6 Sex differences in VZV induced aversive response. Male and female whisker pads were injected with either MeWo cells or MeWo cells
infected with 650 pfu/ μl VZV. PEAP testing was completed weekly over six weeks, each panel shows data for a different week. In panel a the
upper row of asterisks indicate a significant difference between the Female MeWo and Female pOka treatment groups and the lower row of
asterisks indicate a significant difference between the Male MeWo and Male pOka treatment groups. In panels b-f an asterisk indicates a significant
difference (p < 0.05) between the Female MeWo and Female pOka treatment groups. There were 24 control and 25 virus infected females and the
number of males in both the MeWo and pOka treatment groups was 7 for week one, 10 for week two and 15 for weeks three, four, five and six
Stinson et al. BMC Neurology  (2017) 17:95 Page 11 of 15
Zoster-associated pain may last 30–90 days during the
acute phase however, about 20–30% of individuals develop
chronic pain (>90 days) termed post-herpetic neuralgia
(PHN), which may last months to years [6–8, 60, 61]. In
males a VZV dose of 65,000 pfu/whisker pad resulted in a
significant response for one week and a dose of 190,000
pfu/whisker pad resulted in a 7 week response. Assuming
a linear relationship between dosage and response an in-
jection of 300,000 pfu/whisker pad would result in a
12 week response. A 12 week or 90 day pain response is
one of the diagnostic criteria for PHN [60]. Future studies
investigating higher dosages could indicate that this model
is applicable for studying the mechanisms resulting in the
development of PHN.
VZV infection of the whisker pad resulted in IE62 stain-
ing within the V1/V2 and V3 regions of the trigeminal
ganglia. Because the V1/V2 branch innervates the whis-
ker pad it was not clear why some IE62 staining was
Fig. 7 OVX female rats show an increased VZV induced aversive response as compared to males. The whisker pads of male and intact or
ovariectomized (OVX) female rats were injected with either MeWo cells or MeWo cells infected with 650 pfu/μl VZV (Sprague Dawley rats, panels
a and b) or 360 pfu/μl VZV (Long Evans rats, panels c and d). PEAP testing was completed weekly over two weeks. The lower row of asterisks
indicate a significant difference between the Female MeWo and Female pOka treatment groups (both intact and OVX) and the upper row of
asterisks indicate a significant difference between the Male MeWo and Male pOka treatment groups. In panels b and d the bar with an asterisk
indicates a significant difference (p < 0.05) between the Male pOka and the intact and OVX Female pOka treatment groups. In panel c the bar
with an asterisk indicates a significant difference (p < 0.05) between the Male pOka and the intact Female POka treatment groups. The number of
animals in each treatment group was pre-determined and is shown on the figure in parentheses
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present within the V3 region. This is the first evidence
for VZV infection of the trigeminal ganglia after injec-
tion into the rodent whisker pad but VZV is a human
herpes virus, one of eight types of herpes viruses.
Whisker pad injection of herpes simplex virus type 1
(one of the eight types of herpes viruses) resulted in
a small amount of infection of the V3 region with a
majority of the infection being present in the V1/V2
region [62], consistent with our results. Studies of the
somatotopic organization of the trigeminal ganglia
indicated that there was overlap in the ganglionic
regions that contribute to the V1/V2 and V3 branches
[63]. The results could be explained by this overlap; if
some of the IE62 positive neurons in the V3 region
actually project to the whisker pad then it would be
expected that these neurons would become infected
by VZV.
Conclusions
Our study uses behavioral testing to assess zoster asso-
ciated orofacial pain in the rat model. For the first time
a sex difference is shown after VZV injection, consistent
with epidemiological evidence that women report PHN
more than men [24, 25]. This model can be utilized to
study one, the mechanisms of zoster-associated orofacial
pain, two, test drug therapies to treat humans effectively
and three, study the mechanisms contributing to the sex
differences underlying zoster associated pain.
Fig. 8 VZV induced and aversive response that was affected by the estrous cycle. Weekly PEAP testing was completed on cycling female rats
after VZV injection. A total of 24 rats whose whisker pad was injected with MeWo cells and a total of 25 rats whose whisker pad was injected
with MeWo cells infected with 650 pfu/ μl VZV were included in this experiment. Smears were completed on each day of testing and the number of
animals at each cycle phase (i.e., diestrus or proestrus/estrus) was a minimum of 8 rats but that number would vary from week to week depending on
the estrous cycle. Testing was performed once a week for four weeks after whisker pad injection, in panel a testing was completed 1 week after
injection, in panel b 2 weeks after injection, in panel c 3 weeks after injection and in panel d 4 weeks after injection. An asterisk indicates a significant
difference (p < 0.05) between the Diestrus pOka group and the Proestrus/estrus pOka group
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